30 results
8-K
AUTL
Autolus Therapeutics plc
1 Apr 24
Departure of Directors or Certain Officers
7:06am
Officer at Oxford Biomedica, a contract development and manufacturing organization. He previously served as Head of R&D at Swedish Orphan Biovitrum and also
10-K
2023 FY
AUTL
Autolus Therapeutics plc
21 Mar 24
Annual report
4:55pm
, as under such program the trading losses that arise from our qualifying R&D activities can be surrendered for a cash rebate of up to 33.35% of qualifying … to the SME regime on March 4, 2024 which include the introduction of a new rate for R&D intensive companies of 27% (which we may qualify for) and comes
8-K/A
EX-99.1
AUTL
Autolus Therapeutics plc
15 Mar 24
Results of Operations and Financial Condition
4:21pm
as a decrease in our UK reimbursable R&D tax credits claimed through the UK small and medium-size entities. These were partly offset by decreases … in clinical and manufacturing costs associated with the obe-cel clinical program. Please note in prior years, Autolus reported the R&D tax credit as income
8-K
EX-99.2
AUTL
Autolus Therapeutics plc
14 Mar 24
Results of Operations and Financial Condition
12:32pm
382,436 (142,870) Building a fully integrated, next-generation CAR T company 26 1Includes the presentation of our U.K. SME R&D Tax Credit with Income tax … , encouraging EFS and favorable tolerability with low levels of high-grade CRS and ICANS PDUFA date 16 Nov 2024 EMA filing submitted Strategic multi-platform R&D collaboration
8-K
EX-99.1
AUTL
Autolus Therapeutics plc
14 Mar 24
Results of Operations and Financial Condition
12:32pm
payments and employee salaries and related costs, a decrease in our U.K. reimbursable R&D tax credits claimable through the U.K. small and medium-sized … . In prior years, Autolus reported the R&D tax credits as income tax benefit on its statements of operations. The Company has revised its financial
8-K
EX-99.1
60kf57uh0 2k7w9pk
13 Feb 24
Regulation FD Disclosure
4:06pm
8-K
EX-99.2
x93koe
11 Dec 23
Regulation FD Disclosure
8:31am
10-Q
v826cz m1t
9 Nov 23
Quarterly report
4:18pm
6-K
EX-99.2
5jarr
2 Nov 23
Index to Condensed Consolidated Financial Statements
4:26pm
6-K
EX-99.2
hwaohnbpjmzz31
3 Aug 23
Index to Condensed Consolidated Financial Statements
4:32pm
6-K
EX-99.2
omy1em
4 May 23
Index to Condensed Consolidated Financial Statements
4:04pm
424B5
ae9cm3yw73020nssgd
9 Dec 22
Prospectus supplement for primary offering
5:40pm
424B5
mhj386 k3aqfmo
8 Dec 22
Prospectus supplement for primary offering
4:10pm
6-K
EX-1
ypsfge6zv8jgz0a a9
1 Jul 22
Current report (foreign)
5:15pm
6-K
EX-99.2
y05sja3wx7hy8vn5y
3 Nov 21
Index to Condensed Consolidated Financial Statements
4:05pm
6-K
EX-99.2
v9nc35
5 Aug 21
Index to Condensed Consolidated Financial Statements
4:04pm
6-K
EX-1
es6t8hch5ebe w9dk6x
30 Jun 21
Annual Report and Accounts
6:05am
6-K
EX-99.2
5nh1 gosr
6 May 21
Index to Condensed Consolidated Financial Statements
4:05pm